These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 896056)

  • 1. [Effects of pt mutation on various links of closed motor circuits. II. Dopamine metabolites in urine of pt rabbits].
    Osetowska E; Verheyden R; Taraszewska A
    Neuropatol Pol; 1977; 15(3):407-15. PubMed ID: 896056
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of pt mutation on various links of the closed motor circuits. I. Pathomorphology of the neostriatum, the paleostriatum and the substantia nigra in pt rabbits].
    Osetowska E; Luszawski F; Sawicki J
    Neuropatol Pol; 1977; 15(2):263-76. PubMed ID: 887199
    [No Abstract]   [Full Text] [Related]  

  • 3. The excretion of dopamine and dopamine metabolites in Parkinson's disease and the effect of diet thereon.
    Weil-Malherbe H; Van Buren JM
    J Lab Clin Med; 1969 Aug; 74(2):305-18. PubMed ID: 5819684
    [No Abstract]   [Full Text] [Related]  

  • 4. [The role of heredity in Parkinson's disease].
    Atadzhanov M
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):195-9. PubMed ID: 4743268
    [No Abstract]   [Full Text] [Related]  

  • 5. [The reserpine model of parkinsonism and changes in the metabolism of mediators].
    Tret'iakova KA; Samoĭlova ZT
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):220-4. PubMed ID: 4743272
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine and dopamine metabolites in Parkinson's disease-a review.
    Barbeau A
    Proc Aust Assoc Neurol; 1968; 5(1):95-100. PubMed ID: 4885282
    [No Abstract]   [Full Text] [Related]  

  • 7. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 8. Decreased dopamine and homovanillic acid excretion in a case with chlorpromazine-induced Parkinsonism.
    Messiha FS; Turek I
    Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):329-30. PubMed ID: 4734007
    [No Abstract]   [Full Text] [Related]  

  • 9. The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.
    Bronaugh RL; Hattox SE; Hoehn MM; Murphy RC; Rutledge CO
    J Pharmacol Exp Ther; 1975 Dec; 195(3):441-52. PubMed ID: 1195131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
    Jones DG; Lenman JA; Robertson MA; Turnbull MJ
    Br J Pharmacol; 1972 Feb; 44(2):386P-387P. PubMed ID: 4668639
    [No Abstract]   [Full Text] [Related]  

  • 12. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
    Davidson DF; Grosset K; Grosset D
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Catecholamine excretion and treatment of parkinsonism with midantan].
    Kandel' EI; Iadgarov IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Sep; 76(9):1323-6. PubMed ID: 1015136
    [No Abstract]   [Full Text] [Related]  

  • 14. Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease.
    Horellou P; Lundberg C; Le Bourdellès B; Wictorin K; Brundin P; Kalén P; Björklund A; Mallet J
    J Physiol (Paris); 1991; 85(3):158-70. PubMed ID: 1687823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component.
    Perez-Pastene C; Graumann R; Díaz-Grez F; Miranda M; Venegas P; Godoy OT; Layson L; Villagra R; Matamala JM; Herrera L; Segura-Aguilar J
    Neurosci Lett; 2007 May; 418(2):181-5. PubMed ID: 17403576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathogenesis and treatment of manganese induced Parkinsonism].
    Ryzhkova MN; Tarasova LA
    Gig Tr Prof Zabol; 1975 Nov; (11):31-4. PubMed ID: 1205189
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetics of essential tremor.
    Deng H; Le W; Jankovic J
    Brain; 2007 Jun; 130(Pt 6):1456-64. PubMed ID: 17353225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear palsy.
    Oliva R; Pastor P
    Ann Neurol; 2004 Mar; 55(3):448-9. PubMed ID: 14991828
    [No Abstract]   [Full Text] [Related]  

  • 20. [I. Prolegomena to experimental studies on hereditary disease of the nervous system on a "pt" rabbit model].
    Osetowska E; Luszawski F
    Neuropatol Pol; 1975; 13(1):61-70. PubMed ID: 1118061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.